Drug supply management in an umbrella trial requires RTSM configuration that explicitly models arm expansion and arm closure scenarios — not supply planning for the initial design with manual adjustments when the trial evolves. The two most common and preventable supply failures are: resupply shortages following arm expansion (depot inventory configured for initial enrollment rates, not post-expansion demand) and accountability gaps following arm closure (no automated stop on dispensing, no structured inventory reconciliation workflow). Both failures share a root cause: supply was planned for the protocol as written, not for the protocol as it operates.
—
Why Is Umbrella Trial Supply Management Fundamentally Different?
An umbrella trial — testing multiple therapies within one tumor type, with patients assigned to treatment arms based on molecular subtype — presents a supply management challenge unlike any other trial design. The RTSM system must manage multiple investigational agents simultaneously, each potentially from different manufacturers, with different shelf lives, storage requirements, and dispensing schedules. When interim data triggers arm closures or expansions, supply allocation must adjust in real time.
Most supply failures in umbrella trials are predictable. They share a common root cause: supply management was planned for the initial trial design, not for the trial as it actually evolves.
—
What Causes the Arm-Expansion Supply Problem?
When an umbrella trial arm expands based on interim evidence of activity, the supply demand for that arm increases — sometimes rapidly. If depot inventory and resupply triggers are configured for the initial projected enrollment rate rather than the post-expansion rate, sites will experience supply shortages before the resupply system catches up.
The solution is to configure RTSM resupply logic with explicit arm-expansion scenarios modeled in advance. This is a protocol and RTSM design decision, not an operational workaround. It requires the supply management team to work with the statistics team during protocol development to understand the range of plausible enrollment scenarios following a positive interim, and to configure supply buffers accordingly.
—
What Causes the Arm-Closure Waste and Accountability Problem?
When an arm closes based on negative interim data, the remaining inventory allocated to that arm — at depots and sites — must be managed. Unused investigational product creates waste, accountability questions, and in some cases destruction logistics that must be documented for regulatory purposes.
If the RTSM supply allocation system does not have an explicit arm-closure workflow, this is managed manually — with the documentation gaps that typically accompany manual processes.
A well-designed RTSM for umbrella trials includes explicit arm-closure procedures:
- Automated stop on new dispensing for the closed arm
- Site notification with inventory count instructions
- Inventory reconciliation reporting
- Destruction documentation generation
Kyle Hanson, Director of Clinical Operations, Sitero:
“The master protocol governance infrastructure. Sponsors coming from conventional parallel-arm trials are used to a single protocol, a single IND, and a single operations team. An umbrella trial requires a governance model most sponsors have never had to build: a master protocol committee with authority over cross-sub-study decisions; a process for adding, amending, and closing sub-studies without disrupting ongoing arms; clear rules for how IND safety reporting flows when sub-studies have different investigators; and a site contracting structure that can handle sub-study-level activation without requiring full re-initiation every time a new arm opens. The practical failure mode is that the sponsor runs the first sub-study competently, and then when sub-study two or three opens, they realize there’s no established process for how sites consent to the new arm, how RTSM gets updated, or who owns the safety integration. That’s when timelines collapse. The master protocol governance model needs to be designed at the outset, not reverse-engineered when the second sub-study is ready to open.”
—
Arm Expansion vs. Arm Closure: Supply Management Requirements
| Supply Event | What Must Happen | Common Failure Without Pre-Planning |
|---|---|---|
| Arm expansion | Resupply triggers increase to match post-expansion enrollment rate; depot buffers adjusted | Shortage at sites before resupply system catches up |
| Arm closure | Automatic dispensing stop; site notification; inventory reconciliation; destruction documentation | Manual tracking; documentation gaps; regulatory accountability questions |
| New arm addition | Supply kit configuration for new agent; depot setup; import permits if new manufacturer | Weeks of delay while logistics are established outside the RTSM |
| Arm enrollment cap | RTSM gates enrollment at cap; supply allocation does not over-provision | Manual cap enforcement; excess supply allocated to capped arm |
| Multi-manufacturer rebalancing | Unified inventory management across agents | Arm-by-arm manual tracking; cross-agent reconciliation errors |
—
How Does Multi-Manufacturer Coordination Work?
When different arms of an umbrella trial use investigational products from different manufacturers — which is common in industry-sponsored umbrella programs — the supply management complexity increases substantially. Each manufacturer has its own supply chain, quality documentation, and labeling requirements. Depot setup, import permits, and temperature monitoring may differ across agents.
A RTSM system that manages multi-arm supply under a unified inventory management framework — rather than arm-by-arm manual tracking — reduces the coordination overhead and the documentation risk. The alternative is a supply manager maintaining parallel tracking systems for each arm’s investigational product, with manual reconciliation at every dispensing event.
—
What Is Often Forgotten: Companion Diagnostic Supply
Umbrella trials typically require a companion diagnostic or multiplex assay to determine treatment arm assignment. The diagnostic itself is a supply management item: kits, reagents, and in some cases centralized testing capacity must be managed alongside the investigational product supply.
A supply failure in the diagnostic — depleted kits, expired reagents, overloaded central lab capacity — stops enrollment as effectively as a drug supply failure, and is often planned for less rigorously. The companion diagnostic supply chain should be managed with the same RTSM-integrated approach as the investigational product supply.
—
5 Supply Management Requirements to Specify Before Protocol Lock
- Arm expansion scenario modeling: RTSM resupply logic includes at least two plausible enrollment rate scenarios for each arm following a positive interim
- Arm closure workflow: Automated dispensing stop, site notification, and inventory reconciliation are pre-built RTSM functions, not manual procedures
- Multi-manufacturer coordination framework: If arms use products from different manufacturers, a unified inventory management approach is specified before vendor agreements are signed
- Companion diagnostic supply integration: Diagnostic kit and reagent supply is tracked in the same system as investigational product, with coordinated resupply triggers
- Audit-ready dispensing records: Every dispensing event is tied to the specific arm configuration and enrollment rules in effect at the time, supporting regulatory demonstration that the adaptive scheme was implemented as specified
Learn how Sitero manages basket and umbrella trial execution: Basket & Umbrella Trial Execution
Frequently Asked Questions
Q: How does an RTSM handle supply management when a new arm is added mid-study?
A new arm addition mid-study requires supply configuration for a new investigational agent, which may involve depot setup, import permits, temperature monitoring specifications, and kit design — none of which can be done instantly. The operational lead time for adding a new arm’s supply infrastructure should be modeled in the adaptive design plan, so that a positive interim decision that triggers a new arm does not encounter a supply setup delay of weeks before the arm can open.
Q: What documentation is required when investigational product from a closed arm is destroyed?
Destruction documentation requirements vary by regulatory jurisdiction, but generally require a reconciliation of all units dispensed vs. all units returned and destroyed, with chain-of-custody documentation. An RTSM with an explicit arm-closure workflow generates the reconciliation report automatically. Without it, the sponsor reconstructs inventory accountability from dispensing records and site drug accountability logs — a labor-intensive process with documentation risk.
Q: How do you manage supply for umbrella trial arms that have different cold chain requirements?
Each arm’s storage and transport requirements are modeled in the RTSM supply configuration as arm-specific parameters. Sites are notified of the storage requirements for each arm they are activated for. When depot resupply is triggered, the cold chain specifications for the relevant arm’s investigational product govern the shipping method. A unified RTSM that tracks all arms under one system can enforce arm-specific requirements while giving the supply manager a single view across all agents.
—
Planning an oncology trial with umbrella trial supply management requirements?
Sitero has supported 200+ oncology studies across 67+ countries. Talk to an oncology trial expert to discuss your protocol.
—
References
- Sitero. Oncology Program Operational Data. Internal dataset. 200+ oncology studies across 67+ countries. sitero.com/oncology/
- Hanson K. Director of Clinical Operations, Sitero. Expert interview conducted for this article. April 2026.
Running a basket trial operationally requires infrastructure that treats each tumor type cohort as a distinct operational unit within a shared governance framework: cohort-specific site selection (not study-level), a central [...]
A well-governed basket or umbrella trial requires four explicitly designed governance bodies: a Steering Committee with defined decision authority over major protocol changes, an IDMC chartered specifically for adaptive review [...]
